Ph I Study of NBTXR3 With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Trial Profile

Ph I Study of NBTXR3 With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs NBTXR 3 (Primary) ; NBTXR 3 (Primary)
  • Indications Orofacial cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Nanobiotix
  • Most Recent Events

    • 26 Dec 2017 According to a Nanobiotix media release, interim update from the study with high risk elderly patients is expected in 2018.
    • 26 Dec 2017 According to a Nanobiotix media release, in November 2017, the trial's Principal Investigator, presented an update during the Trends in Head and Neck Oncology conference (THNO), with a patient median follow up of 14.2 months, confirming the potential impact of NBTXR3 on the long-term response of the treatment.
    • 06 Jun 2017 Interim results (n=11) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top